FDA/EU Mutual Reliance For GMP Inspections Moving Forward
This article was originally published in The Pink Sheet Daily
Executive Summary
Both sides may agree to overlook “areas of divergence” if they don’t appear significant.
You may also be interested in...
FDA Piloting Oncology Supplement Review Using Only Data Summaries
Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.
FDA Piloting Oncology Supplement Review Using Only Data Summaries
Advantages could be shorter review times and expanded labels, but there are concerns about no global regulator having access to full patient-level data.
FDA Launches Global Rx Quality Initiative With Plans To Rely On Non-U.S. Regulators
Agency restructures staff as it prepares for new U.S.-EU mutual reliance activities to enhance pharmaceutical quality but offers few details on upcoming plans.